Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
Animals
Apoptosis
/ drug effects
Bile Ducts
/ drug effects
Cell Proliferation
/ drug effects
Cysts
/ metabolism
Enzyme Inhibitors
/ pharmacology
Gene Knockdown Techniques
/ methods
Humans
Liver Diseases
/ metabolism
Models, Theoretical
Proteasome Endopeptidase Complex
/ metabolism
RNA, Small Interfering
/ pharmacology
Rats
S-Adenosylmethionine
/ pharmacology
Sumoylation
/ drug effects
Ubiquitin-Conjugating Enzymes
/ antagonists & inhibitors
Hepatic cystogenesis
Post-translational modifications
S-adenosylmethionine (SAMe)
SUMOylation
Therapy
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
15
04
2020
revised:
07
09
2020
accepted:
07
09
2020
pubmed:
21
9
2020
medline:
21
1
2022
entrez:
20
9
2020
Statut:
ppublish
Résumé
Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of multiple fluid-filled biliary cysts. Most PLD-causative genes participate in protein biogenesis and/or transport. Post-translational modifications (PTMs) are implicated in protein stability, localization and activity, contributing to human pathobiology; however, their role in PLD is unknown. Herein, we aimed to unveil the role of protein SUMOylation in PLD and its potential therapeutic targeting. Levels and functional effects of SUMOylation, along with response to S-adenosylmethionine (SAMe, inhibitor of the SUMOylation enzyme UBC9) and/or short-hairpin RNAs (shRNAs) against UBE2I (UBC9), were evaluated in vitro, in vivo and/or in patients with PLD. SUMOylated proteins were determined by immunoprecipitation and proteomic analyses by mass spectrometry. Most SUMOylation-related genes were found overexpressed (mRNA) in polycystic human and rat liver tissue, as well as in cystic cholangiocytes in culture compared to controls. Increased SUMOylated protein levels were also observed in cystic human cholangiocytes in culture, which decreased after SAMe administration. Chronic treatment of polycystic (PCK: Pkdh1-mut) rats with SAMe halted hepatic cystogenesis and fibrosis, and reduced liver/body weight ratio and liver volume. In vitro, both SAMe and shRNA-mediated UBE2I knockdown increased apoptosis and reduced cell proliferation of cystic cholangiocytes. High-throughput proteomic analysis of SUMO1-immunoprecipitated proteins in cystic cholangiocytes identified candidates involved in protein biogenesis, ciliogenesis and proteasome degradation. Accordingly, SAMe hampered proteasome hyperactivity in cystic cholangiocytes, leading to activation of the unfolded protein response and stress-related apoptosis. Cystic cholangiocytes exhibit increased SUMOylation of proteins involved in cell survival and proliferation, thus promoting hepatic cystogenesis. Inhibition of protein SUMOylation with SAMe halts PLD, representing a novel therapeutic strategy. Protein SUMOylation is a dynamic post-translational event implicated in numerous cellular processes. This study revealed dysregulated protein SUMOylation in polycystic liver disease, which promotes hepatic cystogenesis. Administration of S-adenosylmethionine (SAMe), a natural UBC9-dependent SUMOylation inhibitor, halted polycystic liver disease in experimental models, thus representing a potential therapeutic agent for patients.
Sections du résumé
BACKGROUND & AIMS
Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of multiple fluid-filled biliary cysts. Most PLD-causative genes participate in protein biogenesis and/or transport. Post-translational modifications (PTMs) are implicated in protein stability, localization and activity, contributing to human pathobiology; however, their role in PLD is unknown. Herein, we aimed to unveil the role of protein SUMOylation in PLD and its potential therapeutic targeting.
METHODS
Levels and functional effects of SUMOylation, along with response to S-adenosylmethionine (SAMe, inhibitor of the SUMOylation enzyme UBC9) and/or short-hairpin RNAs (shRNAs) against UBE2I (UBC9), were evaluated in vitro, in vivo and/or in patients with PLD. SUMOylated proteins were determined by immunoprecipitation and proteomic analyses by mass spectrometry.
RESULTS
Most SUMOylation-related genes were found overexpressed (mRNA) in polycystic human and rat liver tissue, as well as in cystic cholangiocytes in culture compared to controls. Increased SUMOylated protein levels were also observed in cystic human cholangiocytes in culture, which decreased after SAMe administration. Chronic treatment of polycystic (PCK: Pkdh1-mut) rats with SAMe halted hepatic cystogenesis and fibrosis, and reduced liver/body weight ratio and liver volume. In vitro, both SAMe and shRNA-mediated UBE2I knockdown increased apoptosis and reduced cell proliferation of cystic cholangiocytes. High-throughput proteomic analysis of SUMO1-immunoprecipitated proteins in cystic cholangiocytes identified candidates involved in protein biogenesis, ciliogenesis and proteasome degradation. Accordingly, SAMe hampered proteasome hyperactivity in cystic cholangiocytes, leading to activation of the unfolded protein response and stress-related apoptosis.
CONCLUSIONS
Cystic cholangiocytes exhibit increased SUMOylation of proteins involved in cell survival and proliferation, thus promoting hepatic cystogenesis. Inhibition of protein SUMOylation with SAMe halts PLD, representing a novel therapeutic strategy.
LAY SUMMARY
Protein SUMOylation is a dynamic post-translational event implicated in numerous cellular processes. This study revealed dysregulated protein SUMOylation in polycystic liver disease, which promotes hepatic cystogenesis. Administration of S-adenosylmethionine (SAMe), a natural UBC9-dependent SUMOylation inhibitor, halted polycystic liver disease in experimental models, thus representing a potential therapeutic agent for patients.
Identifiants
pubmed: 32950589
pii: S0168-8278(20)33622-9
doi: 10.1016/j.jhep.2020.09.010
pmc: PMC8157180
mid: NIHMS1666894
pii:
doi:
Substances chimiques
Enzyme Inhibitors
0
RNA, Small Interfering
0
S-Adenosylmethionine
7LP2MPO46S
Ubiquitin-Conjugating Enzymes
EC 2.3.2.23
Proteasome Endopeptidase Complex
EC 3.4.25.1
ubiquitin-conjugating enzyme UBC9
EC 6.3.2.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
394-406Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK084567
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK024031
Pays : United States
Informations de copyright
Copyright © 2020 European Association for the Study of the Liver. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Hepatology. 2012 Sep;56(3):982-93
pubmed: 22407595
Anat Rec (Hoboken). 2010 Aug;293(8):1279-88
pubmed: 20665806
Anticancer Res. 2013 Nov;33(11):4683-94
pubmed: 24222102
Gut. 2014 Oct;63(10):1658-67
pubmed: 24436140
Liver Int. 2020 Jul;40(7):1670-1685
pubmed: 32378324
Lab Invest. 2006 Sep;86(9):940-50
pubmed: 16783394
J Hepatol. 2018 Apr;68(4):827-837
pubmed: 29175241
Am J Hum Genet. 2016 Jun 2;98(6):1193-1207
pubmed: 27259053
EBioMedicine. 2019 Feb;40:406-421
pubmed: 30594553
PLoS One. 2015 Mar 16;10(3):e0122124
pubmed: 25774783
J Clin Psychiatry. 2017 Jun;78(6):e656-e667
pubmed: 28682528
Transl Gastroenterol Hepatol. 2018 Apr 23;3:20
pubmed: 29780898
Nat Rev Gastroenterol Hepatol. 2014 Dec;11(12):750-61
pubmed: 25266109
Am J Pathol. 2004 Nov;165(5):1719-30
pubmed: 15509540
J Clin Invest. 2017 Feb 1;127(2):583-592
pubmed: 28094767
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):269-281
pubmed: 30850822
Biomol Concepts. 2017 Mar 1;8(1):13-36
pubmed: 28284030
J Hepatol. 1999 Jun;30(6):1081-9
pubmed: 10406187
IUBMB Life. 2014 Feb;66(2):71-7
pubmed: 24470405
Biochem Pharmacol. 2011 Nov 1;82(9):1110-25
pubmed: 21819973
Hepatology. 2007 May;45(5):1306-12
pubmed: 17464973